Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia

References

• Jemal A, Tiwari R, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54(1):8–29. doi:10.3322/canjclin.54.1.8
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485. doi:10.1182/blood-2005-09-3724
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474. doi:10.1182/blood-2009-07-235358
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422–4429. doi:10.1182/blood-2010-03-276485
   PubMed Web of Science ®Google Scholar
• Short N, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica. 2019;104(8):1532–1541. doi:10.3324/haematol.2018.208454
   PubMed Web of Science ®Google Scholar
• Buccisano F, Dillon R, Freeman SD, Venditti A. Role of minimal (measurable) residual disease assessment in older patients with acute myeloid leukemia. Cancers. 2018;10(7):215. doi:10.3390/cancers10070215
   PubMed Web of Science ®Google Scholar
• Gale RP, Hochhaus A. Therapy of older persons with acute myeloid leukemia. Leukemia. 2015;29(4):759. doi:10.1038/leu.2014.337
   PubMed Web of Science ®Google Scholar
• McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878–1887. doi:10.1200/JCO.2009.25.4821
   PubMed Web of Science ®Google Scholar
• Boddu P, Jorgensen J, Kantarjian H, et al. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. 2018;32(1):241–244. doi:10.1038/leu.2017.285
   PubMed Web of Science ®Google Scholar
• Foran J. Frontline therapy of AML: should the older patient be treated differently?. Curr Hematol Malig Rep. 2014;9(2):100–108. doi:10.1007/s11899-014-0211-8
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood. 2018;131(12):1275–1291. doi:10.1182/blood-2017-09-801498
   PubMed Web of Science ®Google Scholar
• Hourigan C, Karp J. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013;10(8):460–471. doi:10.1038/nrclinonc.2013.100
   PubMed Web of Science ®Google Scholar
• Hokland P, Ommen H. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood. 2011;117(9):2577–2584. doi:10.1182/blood-2010-09-303685
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Del Principe M, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119(2):332–341. doi:10.1182/blood-2011-08-363291
   PubMed Web of Science ®Google Scholar
• Fuda F, Chen W. Minimal/measurable residual disease detection in acute leukemias by multiparameter flow cytometry. Curr Hematol Malig Rep. 2018;13(6):455–466. doi:10.1007/s11899-018-0479-1
   PubMed Web of Science ®Google Scholar
• Freeman S, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31(32):4123–4131. doi:10.1200/jco.2013.49.1753
   PubMed Web of Science ®Google Scholar
• Ravandi F, Walter R, Freeman S. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018;2(11):1356–1366. doi:10.1182/bloodadvances.2018016378
   PubMed Web of Science ®Google Scholar
• Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742–752. doi:10.1182/blood-2017-02-769869
   PubMed Web of Science ®Google Scholar
• Corces-Zimmerman MR, Majeti R. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia. 2014;28(12):2276–2282. doi:10.1038/leu.2014.211
   PubMed Web of Science ®Google Scholar
• Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732–741. doi:10.1182/blood-2017-04-779447
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. New Engl J Med. 2014;371(26):2477–2487. doi:10.1056/NEJMoa1409405
   PubMed Web of Science ®Google Scholar
• Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114(11):2220–2231. doi:10.1182/blood-2009-03-213389
   PubMed Web of Science ®Google Scholar
• Pratcorona M, Brunet S, Nomdedeu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121(14):2734–2738. doi:10.1182/blood-2012-06-431122
   PubMed Web of Science ®Google Scholar
• Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK national cancer research institute/medical research council report. J Clin Oncol. 2015;33(15):1715. doi:10.1200/Jco.2015.62.4288
   PubMed Web of Science ®Google Scholar
• Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747–4753. doi:10.1200/JCO.2008.21.0674
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G, Schuurhuis G. MRD in AML: does it already guide therapy decision-making? Hematology Am Soc Hematol Educ Program. 2016;2016(1):356–365. doi:10.1182/asheducation-2016.1.356
   PubMedGoogle Scholar
• Nomdedéu J, Hoyos M, Carricondo M, et al. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia. 2013;27(11):2157–2164. doi:10.1038/leu.2013.111
   PubMed Web of Science ®Google Scholar
• Short N, Rytting M, Cortes J. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606. doi:10.1016/s0140-6736(18)31041-9
   PubMed Web of Science ®Google Scholar
• Prassek VV, Rothenberg-Thurley M, Sauerland MC, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853–1861. doi:10.3324/haematol.2018.191536
   PubMed Web of Science ®Google Scholar
• Aitken M, Ravandi F, Patel K, Short N. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. J Hematol Oncol. 2021;14(1):137. doi:10.1186/s13045-021-01148-5
   PubMed Web of Science ®Google Scholar
• Smol T, Nibourel O, Marceau-Renaut A, et al. Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: a study by the ALFA Group. Leuk Res. 2015;39(12):1443–1447. doi:10.1016/j.leukres.2015.09.021
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–5201. doi:10.1200/Jco.2009.22.4865
   PubMed Web of Science ®Google Scholar
• Gianfaldoni G, Mannelli F, Ponziani V, et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematol Hematol J. 2010;95(5):833–836. doi:10.3324/haematol.2009.011908
   PubMed Web of Science ®Google Scholar
• Patkar N, Kakirde C, Shaikh AF, et al. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia. 2021;35(5):1392–1404. doi:10.1038/s41375-021-01131-6
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category. Blood. 2011;118(26):6920–6929. doi:10.1182/blood-2011-08-368225
   PubMed Web of Science ®Google Scholar
• Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012;30(25):3109–3118. doi:10.1200/JCO.2011.40.6652
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Paschka P, Spath D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012;30(12):1350–1357. doi:10.1200/JCO.2011.39.2886
   PubMed Web of Science ®Google Scholar
• Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–2121. doi:10.1182/blood-2011-08-375758
   PubMed Web of Science ®Google Scholar
• Young AL, Wong TN, Hughes AE, et al. Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing. Leukemia. 2015;29(7):1608–1611. doi:10.1038/leu.2015.17
   PubMed Web of Science ®Google Scholar
• Hiatt JB, Pritchard CC, Salipante SJ, O’Roak BJ, Shendure J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 2013;23(5):843–854. doi:10.1101/gr.147686.112
   PubMed Web of Science ®Google Scholar
• Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A. 2012;109(36):14508–14513. doi:10.1073/pnas.1208715109
   PubMed Web of Science ®Google Scholar
• Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood. 2014;124(23):3345–3355. doi:10.1182/blood-2014-05-577593
   PubMed Web of Science ®Google Scholar
• Mrozek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30(36):4515–4523. doi:10.1200/Jco.2012.43.4738
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686–698. doi:10.1182/blood-2016-01-693879
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299. doi:10.1182/blood-2015-01-621664
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677. doi:10.1200/jco.2011.38.9429
   PubMed Web of Science ®Google Scholar
• Schuh AC, Dohner H, Pleyer L, Seymour JF, Fenaux P, Dombret H. Azacitidine in adult patients with acute myeloid leukemia. Crit Rev Oncol Hematol. 2017;116:159–177. doi:10.1016/j.critrevonc.2017.05.010
   PubMed Web of Science ®Google Scholar
• Kadia TM, Cortes J, Ravandi F, et al. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a Phase 2 single-arm trial. Lancet Haematol. 2018;5(9):e411–e421. doi:10.1016/S2352-3026(18)30132-7
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Maiti A, DiNardo C, Wang S, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021;5(7):1876–1883. doi:10.1182/bloodadvances.2020003717
   PubMed Web of Science ®Google Scholar
• Kadia TM, Reville PK, Wang X, et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022;40(33):3848–3857. doi:10.1200/JCO.21.02823
   PubMed Web of Science ®Google Scholar
• Simoes C, Paiva B, Martinez-Cuadron D, et al. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Adv. 2021;5(3):760–770. doi:10.1182/bloodadvances.2020003195
   PubMed Web of Science ®Google Scholar
• Hilberink JR, Morsink LM, van der Velden W, et al. Pretransplantation MRD in older patients with AML after treatment with decitabine or conventional chemotherapy. Transplant Cell Ther. 2021;27(3):246–252. doi:10.1016/j.jtct.2020.12.014
   PubMedGoogle Scholar
• Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29(1):137–144. doi:10.1038/leu.2014.173
   PubMed Web of Science ®Google Scholar
• Foran JM, Sun ZX, Paietta E, et al. Minimal Residual Disease (MRD) at time of complete remission is commonly detected in Acute Myeloid Leukemia (AML) patients age ≥ 60 years and significantly impacts outcome based on post-remission treatment strategies: prospective analysis of ECOG-ACRIN (E-A) E2906 phase III trial. Blood. 2018;132. doi:10.1182/blood-2018-99-113950
   Web of Science ®Google Scholar
• Roboz GJ, Ravandi F, Wei AH, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022;139(14):2145–2155. doi:10.1182/blood.2021013404
   PubMed Web of Science ®Google Scholar
• Oliai C, Schiller G. How to address second and therapy-related acute myelogenous leukaemia. Br J Haematol. 2020;188(1):116–128. doi:10.1111/bjh.16354
   PubMed Web of Science ®Google Scholar
• Walter R, Buckley S, Pagel J, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813–1821. doi:10.1182/blood-2013-06-506725
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja M. Guadecitabine for AML and MDS: hype or hope? Lancet Oncol. 2015;16(9):1009–1011. doi:10.1016/s1470-2045(15)00095-9
   PubMed Web of Science ®Google Scholar
• Wei A, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526–2537. doi:10.1056/NEJMoa2004444
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Piciocchi A, et al. Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. Ann Hematol. 2015;94(8):1319–1326. doi:10.1007/s00277-015-2364-5
   PubMed Web of Science ®Google Scholar
• Cornelissen J, Gratwohl A, Schlenk R, et al. The European LeukemiaNet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579–590. doi:10.1038/nrclinonc.2012.150
   PubMed Web of Science ®Google Scholar
• Appelbaum FR. Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML). Best Pract Res Clin Haematol. 2008;21(1):85–92. doi:10.1016/j.beha.2007.11.013
   PubMed Web of Science ®Google Scholar
• Ustun C, Lazarus H, Weisdorf D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant. 2013;48(12):1497–1505. doi:10.1038/bmt.2013.67
   PubMed Web of Science ®Google Scholar